Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brandon Howard

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Contraception|March 10, 2015
Ovulatory effects of three oral contraceptive regimens: a randomized, open-label, descriptive trialLarry Seidman, Robin Kroll, Brandon Howard, et al.
American Journal of Obstetrics and Gynecology|March 11, 2021
EVO100 prevents chlamydia and gonorrhea in women at high risk of infectionB Todd Chappell, Leandro A Mena, Basem Maximos, et al.
Contraception|October 27, 2015
Efficacy and safety of a 21/7-active combined oral contraceptive with continuous low-dose ethinyl estradiolRobin Kroll, Ronald Ackerman, Robert Feldman, et al.
Cancer Research|April 3, 2003
Protein expression profiling identifies macrophage migration inhibitory factor and cyclophilin a as potential molecular targets in non-small cell lung cancerMichael J Campa, Michael Z Wang, Brandon Howard, et al.
Proteomics|September 16, 2003
Analysis of human serum proteins by liquid phase isoelectric focusing and matrix-assisted laser desorption/ionization-mass spectrometryMichael Z Wang, Brandon Howard, Michael J Campa, et al.
The European Journal of Contraception & Reproductive Health Care : the Official Journal of the European Society of Contraception|June 27, 2015
Differences in reporting Pearl Indices in the United States and Europe: Focus on a 91-day extended-regimen combined oral contraceptive with low-dose ethinyl estradiol supplementationPaloma Lobo Abascal, Vesna Luzar-Stiffler, Silvana Giljanovic, et al.
Contraception|March 1, 2014
Efficacy and safety of an ascending-dose, extended-regimen levonorgestrel/ethinyl estradiol combined oral contraceptiveDavid J Portman, Andrew M Kaunitz, Brandon Howard, et al.
Contraception: X|July 21, 2020
A novel vaginal pH regulator: results from the phase 3 AMPOWER contraception clinical trialMichael A Thomas, B Todd Chappell, Bassem Maximos, et al.
The European Journal of Contraception & Reproductive Health Care : the Official Journal of the European Society of Contraception|June 14, 2014
Multinational, multicentre, randomised, open-label study evaluating the impact of a 91-day extended regimen combined oral contraceptive, compared with two 28-day traditional combined oral contraceptives, on haemostatic parameters in healthy womenRossella E Nappi, Anna Maria Paoletti, Annibale Volpe, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 3, 2020
First Mildly Ill, Nonhospitalized Case of Coronavirus Disease 2019 (COVID-19) Without Viral Transmission in the United States-Maricopa County, Arizona, 2020Sarah E Scott, Karen Zabel, Jennifer Collins, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Contraception|March 10, 2015
Ovulatory effects of three oral contraceptive regimens: a randomized, open-label, descriptive trialLarry Seidman, Robin Kroll, Brandon Howard, et al.
American Journal of Obstetrics and Gynecology|March 11, 2021
EVO100 prevents chlamydia and gonorrhea in women at high risk of infectionB Todd Chappell, Leandro A Mena, Basem Maximos, et al.
Contraception|October 27, 2015
Efficacy and safety of a 21/7-active combined oral contraceptive with continuous low-dose ethinyl estradiolRobin Kroll, Ronald Ackerman, Robert Feldman, et al.
Cancer Research|April 3, 2003
Protein expression profiling identifies macrophage migration inhibitory factor and cyclophilin a as potential molecular targets in non-small cell lung cancerMichael J Campa, Michael Z Wang, Brandon Howard, et al.
Proteomics|September 16, 2003
Analysis of human serum proteins by liquid phase isoelectric focusing and matrix-assisted laser desorption/ionization-mass spectrometryMichael Z Wang, Brandon Howard, Michael J Campa, et al.
The European Journal of Contraception & Reproductive Health Care : the Official Journal of the European Society of Contraception|June 27, 2015
Differences in reporting Pearl Indices in the United States and Europe: Focus on a 91-day extended-regimen combined oral contraceptive with low-dose ethinyl estradiol supplementationPaloma Lobo Abascal, Vesna Luzar-Stiffler, Silvana Giljanovic, et al.
Contraception|March 1, 2014
Efficacy and safety of an ascending-dose, extended-regimen levonorgestrel/ethinyl estradiol combined oral contraceptiveDavid J Portman, Andrew M Kaunitz, Brandon Howard, et al.
Contraception: X|July 21, 2020
A novel vaginal pH regulator: results from the phase 3 AMPOWER contraception clinical trialMichael A Thomas, B Todd Chappell, Bassem Maximos, et al.
The European Journal of Contraception & Reproductive Health Care : the Official Journal of the European Society of Contraception|June 14, 2014
Multinational, multicentre, randomised, open-label study evaluating the impact of a 91-day extended regimen combined oral contraceptive, compared with two 28-day traditional combined oral contraceptives, on haemostatic parameters in healthy womenRossella E Nappi, Anna Maria Paoletti, Annibale Volpe, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 3, 2020
First Mildly Ill, Nonhospitalized Case of Coronavirus Disease 2019 (COVID-19) Without Viral Transmission in the United States-Maricopa County, Arizona, 2020Sarah E Scott, Karen Zabel, Jennifer Collins, et al.
Pageof 2